chitosan has been researched along with exenatide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, SC; Kim, TH; Lee, C; Lee, ES; Lee, J; Lee, KC; Park, ES; Shin, BS; Youn, YS | 1 |
| Chen, Y; Feng, J; Kong, W; Li, C; Liu, B; Sun, B; Wang, M; Zhang, H; Zhang, Y | 1 |
| Chen, Y; Dong, Q; Feng, J; Gu, T; Kong, W; Sun, Y; Wang, M; Wu, Y; Yang, X; Zhang, Y | 1 |
| Ahn, S; Jon, S; Kim, H; Kim, YC; Lee, E; Lee, IH | 1 |
| Chen, CT; Chuang, EY; Juang, JH; Lin, KJ; Mi, FL; Nguyen, GT; Su, FY; Sung, HW; Yen, TC | 1 |
| Choi, JS; Kim, I; Lee, C; Lee, ES; Lee, KC; Oh, KT; Park, ES; Youn, YS | 1 |
| Byeon, HJ; Choi, JS; Kim, I; Kim, TH; Lee, C; Lee, ES; Lee, KC; Oh, KT; Youn, YS | 1 |
| Chen, Y; Gong, X; Kong, W; Sun, B; Sun, Y; Wang, M; Wu, Y; Zhang, X; Zhang, Y | 1 |
| Li, X; Li, Y; Liang, R; Liu, W; Shi, Y; Sun, F; Sun, K; Wang, A; Wang, C | 1 |
| Chae, SY; Kim, K; Lee, KC; Lim, SM; Na, DH; Park, EJ; Son, S | 1 |
| Han, L; Hong, A; Li, YW; Ma, M; Ma, Y; Wan, DC; Wang, DH; Xiao, X; Zhao, SJ | 1 |
| Guo, H; Tang, H; Yan, X; Zhang, X | 1 |
| Peng, Y; Qiu, L; Xie, P | 1 |
| Huynh, DP; Kim, J; Le, TMD; Lee, DS; Nguyen, HT; Nguyen, TL; Trinh, TA | 1 |
14 other study(ies) available for chitosan and exenatide
| Article | Year |
|---|---|
Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.
Topics: Acylation; Administration, Inhalation; Animals; Chitosan; Desoxycorticosterone; Diabetes Mellitus; Drug Carriers; Exenatide; Gels; Hypoglycemic Agents; Lung; Male; Mice; Mice, Inbred ICR; Nanostructures; Palmitic Acid; Peptides; Venoms | 2012 |
Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers.
Topics: Animals; Biological Transport; Cell Line; Chitosan; Decanoic Acids; Dogs; Edetic Acid; Exenatide; Humans; Intestinal Absorption; Intestinal Mucosa; Kidney; Peptides; Permeability; Venoms | 2012 |
Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
Topics: Amiloride; Animals; Cell Survival; Chitosan; Chlorpromazine; Dogs; Drug Carriers; Exenatide; Intestinal Absorption; Lactic Acid; Madin Darby Canine Kidney Cells; Male; Models, Biological; Nanoparticles; Particle Size; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Spectrometry, Fluorescence; Venoms | 2013 |
Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
Topics: Administration, Oral; Animals; Cell Line, Tumor; Chitosan; Diabetes Mellitus; Exenatide; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Molecular Weight; Peptides; Rats; Venoms | 2013 |
Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
Topics: Administration, Oral; Animals; Cattle; Chitosan; Diabetes Mellitus, Experimental; Drug Combinations; Drug Delivery Systems; Exenatide; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Intestinal Absorption; Nanoparticles; Particle Size; Peptides; Polyglutamic Acid; Rats; Rats, Wistar; Venoms | 2013 |
Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Topics: Administration, Inhalation; Adsorption; Analysis of Variance; Animals; Blood Glucose; Cell Line; Cell Survival; Chitosan; Diabetes Mellitus, Type 2; Drug Carriers; Exenatide; Humans; Hydrophobic and Hydrophilic Interactions; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties; Venoms | 2013 |
Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.
Topics: Adsorption; Animals; Cell Death; Chitosan; Decanoic Acids; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Exenatide; Fasting; Hydrogels; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Melanoma, Experimental; Mice; Microscopy, Electron, Scanning; Molecular Weight; Peptides; Tissue Distribution; Venoms | 2014 |
Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine.
Topics: Animals; Cell Membrane Permeability; Chemistry, Pharmaceutical; Chitosan; Dogs; Exenatide; Intestinal Absorption; Intestine, Small; Madin Darby Canine Kidney Cells; Models, Animal; Nanoparticles; Particle Size; Peptides; Polyphosphates; Rats; Surface Properties; Tight Junctions; Venoms | 2014 |
The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
Topics: Administration, Oral; Animals; Biotransformation; Blood Glucose; Caco-2 Cells; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Exenatide; Goblet Cells; HT29 Cells; Humans; Hypoglycemic Agents; Intestinal Absorption; Male; Nanomedicine; Nanoparticles; Oligopeptides; Peptides; Permeability; Rats, Sprague-Dawley; Technology, Pharmaceutical; Tissue Distribution; Venoms | 2015 |
Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Topics: Animals; Chitosan; Diabetes Mellitus, Type 2; Drug Carriers; Drug Liberation; Exenatide; Hypoglycemic Agents; Lithocholic Acid; Lysine; Mice; Nanoparticles; Particle Size; Peptides; Succinimides; Venoms | 2015 |
A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.
Topics: Animals; Blood Glucose; Cell Proliferation; Chitosan; Diabetes Mellitus, Type 2; Drug Liberation; Exenatide; Fasting; Glucose; Half-Life; Hydrogen Peroxide; Insulin; Insulin Resistance; Male; Mice; Nanoparticles; Peptides; Reactive Oxygen Species; Receptor, Insulin; Receptors, Vasoactive Intestinal Peptide, Type II; RNA, Messenger; Selenium; Venoms | 2017 |
Assessment of Exenatide loaded Biotinylated Trimethylated Chitosan/HP- 55 Nanoparticles.
Topics: Animals; Chitosan; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Carriers; Exenatide; Humans; Methylcellulose; Mice; Nanoparticles; Particle Size; Spectroscopy, Fourier Transform Infrared; Tissue Distribution | 2022 |
Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1.
Topics: Animals; Chitosan; Diet, High-Fat; Exenatide; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligosaccharides; Sirtuin 1; Ursodeoxycholic Acid | 2022 |
pH-temperature Responsive Hydrogel-Mediated Delivery of Exendin-4 Encapsulated Chitosan Nanospheres for Sustained Therapeutic Efficacy in Type 2 Diabetes Mellitus.
Topics: Chitosan; Diabetes Mellitus, Type 2; Exenatide; Humans; Hydrogels; Hydrogen-Ion Concentration; Nanospheres; Temperature | 2023 |